Intracellular proton conductance of the hepatitis C virus p7 protein and its contribution to infectious virus production.
The hepatitis C virus (HCV) p7 protein is critical for virus production and an attractive antiviral target. p7 is an ion channel when reconstituted in artificial lipid bilayers, but channel function has not been demonstrated in vivo and it is unknown whether p7 channel activity plays a critical role in virus production. To evaluate the contribution of p7 to organelle pH regulation and virus production, we incorporated a fluorescent pH sensor within native, intracellular vesicles in the presence or absence of p7 expression. p7 increased proton (H(+)) conductance in vesicles and was able to rapidly equilibrate H(+) gradients. This conductance was blocked by the viroporin inhibitors amantadine, rimantadine and hexamethylene amiloride. Fluorescence microscopy using pH indicators in live cells showed that both HCV infection and expression of p7 from replicon RNAs reduced the number of highly acidic (pH<5) vesicles and increased lysosomal pH from 4.5 to 6.0. These effects were not present in uninfected cells, sub-genomic replicon cells not expressing p7, or cells electroporated with viral RNA containing a channel-inactive p7 point mutation. The acidification inhibitor, bafilomycin A1, partially restored virus production to cells electroporated with viral RNA containing the channel inactive mutation, yet did not in cells containing p7-deleted RNA. Expression of influenza M2 protein also complemented the p7 mutant, confirming a requirement for H(+) channel activity in virus production. Accordingly, exposure to acid pH rendered intracellular HCV particles non-infectious, whereas the infectivity of extracellular virions was acid stable and unaffected by incubation at low pH, further demonstrating a key requirement for p7-induced loss of acidification. We conclude that p7 functions as a H(+) permeation pathway, acting to prevent acidification in otherwise acidic intracellular compartments. This loss of acidification is required for productive HCV infection, possibly through protecting nascent virus particles during an as yet uncharacterized maturation process.
Wozniak
Ann L
AL
Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA.
Griffin
Stephen
S
Rowlands
David
D
Harris
Mark
M
Yi
MinKyung
M
Lemon
Stanley M
SM
Weinman
Steven A
SA
D000547:Amantadine / Q000494:pharmacology; D000935:Antifungal Agents / Q000494:pharmacology; D000998:Antiviral Agents / Q000494:pharmacology; D015153:Blotting, Western; D018274:Electroporation; D016174:Hepacivirus / Q000502:physiology*; D006526:Hepatitis C / Q000378:metabolism* / Q000821:virology*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007473:Ion Channels / Q000187:drug effects; D007668:Kidney / Q000166:cytology / Q000378:metabolism / Q000821:virology; D008051:Lipid Bilayers / Q000378:metabolism; D018942:Macrolides / Q000494:pharmacology; D009154:Mutation / Q000235:genetics; D011522:Protons; D012367:RNA, Viral / Q000235:genetics; D012299:Rimantadine / Q000494:pharmacology; D013347:Subcellular Fractions; D014158:Transcription, Genetic; D014764:Viral Proteins / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D014771:Virion / Q000502:physiology*; D053586:Virus Internalization / Q000187:drug effects; D014779:Virus Replication; D000086082:Viroporin Proteins
D000547:Amantadine; D000935:Antifungal Agents; D000998:Antiviral Agents; D007473:Ion Channels; D008051:Lipid Bilayers; D018942:Macrolides; D011522:Protons; D012367:RNA, Viral; D012299:Rimantadine; D014764:Viral Proteins; C088369:p7 protein, Hepatitis C virus; D000086082:Viroporin Proteins; C040929:bafilomycin A1
J Biol Chem. 2008 Mar 28;283(13):8089-101
18198177
J Virol. 2007 Jan;81(2):629-38
17079282
J Virol. 2004 Jan;78(1):502-7
14671130
J Virol. 2009 Aug;83(16):7970-81
19493992
Hepatology. 2008 Dec;48(6):1779-90
18828153
J Neurochem. 2008 Dec;107(6):1709-21
19014382
Virology. 2002 Dec 20;304(2):197-210
12504562
J Biol Chem. 2006 Dec 1;281(48):37057-68
17032656
J Virol. 2005 Dec;79(24):15525-36
16306623
J Virol. 2001 Jun;75(12):5656-62
11356973
FEBS Lett. 2003 Sep 18;552(1):28-34
12972148
FEBS Lett. 2003 Sep 18;552(1):61-7
12972153
Proc Natl Acad Sci U S A. 2003 May 13;100(10):6104-8
12719519
J Virol. 2000 Oct;74(20):9498-506
11000219
J Viral Hepat. 2010 Nov;17(11):784-93
20002299
Am J Physiol. 1985 Mar;248(3 Pt 1):C372-8
2579573
J Cell Biol. 1996 May;133(4):733-47
8666660
PLoS Pathog. 2007 Jul;3(7):e103
17658949
J Biol Chem. 2006 Apr 7;281(14):8997-9000
16407184
Nat Protoc. 2006;1(5):2334-9
17406476
J Med Chem. 2006 Jan 26;49(2):648-55
16420050
J Virol. 2006 Feb;80(4):1734-41
16439530
Antiviral Res. 2006 Mar;69(3):129-41
16413618
J Virol. 2007 Aug;81(16):8374-83
17537845
J Virol. 2002 Feb;76(3):1391-9
11773413
J Virol. 2002 Apr;76(8):3720-30
11907211
Hepatology. 2008 Nov;48(5):1404-11
18846541
J Gen Virol. 2004 Feb;85(Pt 2):451-461
14769903
Microbes Infect. 2008 Jul;10(9):960-7
18672082
FEBS Lett. 2003 Jan 30;535(1-3):34-8
12560074
Curr Pharm Des. 2007;13(31):3231-5
18045172
Acta Microbiol Immunol Hung. 2003;50(4):433-42
14750442
Antiviral Res. 2007 Oct;76(1):48-58
17574688
Photochem Photobiol Sci. 2006 Jun;5(6):629-32
16761092
J Virol. 2009 Nov;83(22):11682-93
19726506
Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12712-6
19590017
FEBS Lett. 2004 Jan 16;557(1-3):99-103
14741348
Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11646-51
14504405